Blockbuster products are generally those believed to produce over a billion a year in revenue. I don't believe that anyone would deny that in GBM alone DCVax-L wouldn't be a blockbuster drug.
Companies with approved products that sell a few million dollars a year certainly don't warrant billion dollar market caps.
DCVax-L will be a new paradigm in the treatment of cancer, it won't take that long for the medical community to recognize it, but we need that initial approval to get things started. I still think it's likely this year.
Market Data 
Markets 
AI
